Richard Vandivier is a Respiratory physician.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
12605 E 16th Ave
Aurora, CO 800452545
Telephone
720-848-0000Registry record last updated 3 Jan 2011.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
76%Corticosteroid36.8%Trelegy Ellipta44%Fluticasone Propionate22%Symbicort13%Breo Ellipta12%Arnuity Ellipta9%Part D<11 patientsbeta2-Adrenergic Agonist30.7%Albuterol Sulfate Hfa81%Ventolin Hfa19%Part D≥39 patients+ 2 more classes in this area
Dermatology
8.2%Interleukin-4 Receptor alpha Antagonist8.2%Dupixent Pen100%Part D<11 patientsAnti-infectives
8%Macrolide Antimicrobial5.3%Azithromycin100%Part D≥11 patientsPenicillins with extended spectrum2.7%Amoxicillin-Clavulanate Potass100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
3 NIH research awards on record, funded 2003–2026 per NIH RePORTER. The latest:
- Airway Basal Progenitor Dysfunction in the Detection, Progression and Pathogenesis of Early COPD
University of Colorado Denver
FY2026$687,103R01HL164555 - Airway Basal Progenitor Dysfunction in the Detection, Progression and Pathogenesis of Early COPD
University of Colorado Denver
FY2025$701,805R01HL164555 - Airway Basal Progenitor Dysfunction in the Detection, Progression and Pathogenesis of Early COPD
University of Colorado Denver
FY2024$694,181R01HL164555
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Tim Driscoll
The University of Sydney
Francesco Saverio Violante
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola
Mark A. Rubin
University of Bern
Marc Humbert
Inserm
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”